Domov › Rakovina prsníka › Alabama
Klinické štúdie Rakovina prsníka v štáte Alabama
29 štúdií pre Rakovina prsníka hľadá účastníkov v zariadeniach v štáte Alabama.
Mestá v štáte Alabama
Oficiálny text štúdie (anglicky)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Central Alabama Research, Birmingham
Prebieha náborFáza 3
Vek 18 až 100 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT05827081A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06760819A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Alabama Oncology, Birmingham
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06369285PRE-ISPY Phase I/II Oncology Platform Program
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT05868226Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
- University of Alabama at Birmingham, Birmingham
Prebieha náborFáza 2
Vek 60 a viac · Ženy · Aktualizované 30. 9. 2026 · NCT06105684A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Southern Cancer Center (SCC) ( Site 8000), Daphne
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07060807An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
- University of Alabama At Birmingham Hospital, Birmingham
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07222267A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Daphne
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06103864Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
- The Kirklin Clinic, Birmingham
Prebieha nábor
Vek 18 až 90 · Ženy · Aktualizované 25. 9. 2026 · NCT06294574A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT06618287A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of Alabama at Birmingham, Birmingham
Prebieha náborFáza 2
Vek 18 a viac · Ženy · Aktualizované 22. 9. 2026 · NCT07287098Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- University of Alabama at Birmingham, Birmingham
Prebieha náborVítaní zdravých dobrovoľníkov
Vek 30 až 74 · Ženy · Aktualizované 21. 9. 2026 · NCT02620852A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Southern Cancer Center, PC, Daphne
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 15. 9. 2026 · NCT06492616Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 10. 9. 2026 · NCT06293898Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Birmingham Hematology Associates, Birmingham
Prebieha náborObservačná štúdia
Vek 18 až 99 · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT07211178TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- University of Alabama, Birmingham
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 26. 8. 2026 · NCT06533826Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Southern Cancer Center, Mobile
Prebieha náborFáza 3
Vek 18 až 100 · Všetky pohlavia · Aktualizované 6. 8. 2026 · NCT05232916Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
- University of Alabama, Birmingham, Birmingham
Prebieha náborVítaní zdravých dobrovoľníkov
Vek 45 až 74 · Ženy · Aktualizované 31. 7. 2026 · NCT05625659Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Uni of Alabama at Birmingham, Birmingham
Prebieha náborFáza 1
Vek 18 až 100 · Všetky pohlavia · Aktualizované 29. 7. 2026 · NCT06562192Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
- The University of Alabama, Birmingham
Prebieha nábor
Vek 18 a viac · Všetky pohlavia · Aktualizované 15. 5. 2026 · NCT06855654I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Alabama at Birmingham, Birmingham
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 6. 5. 2026 · NCT01042379Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- University of Alabama at Birmingham, Birmingham
- University of South Alabama, Mobile
Prebieha nábor
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 4. 2026 · NCT05297734De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- University of South Alabama Mitchell Cancer Institute, Mobile
Prebieha náborFáza 3
Vek 50 až 70 · Všetky pohlavia · Aktualizované 23. 4. 2026 · NCT04852887A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- University of Alabama at Birmingham, Birmingham
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 2. 2026 · NCT06099769Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
- The Kirklin Clinic, Birmingham
Prebieha náborSkorá fáza 1
Vek 18 a viac · Ženy · Aktualizované 26. 1. 2026 · NCT03321045Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
- University of Alabama Birmingham, Birmingham
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 20. 1. 2026 · NCT05693766Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- The University of Alabama at Birmingham, Birmingham
Prebieha nábor
Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 12. 2025 · NCT04722341RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
- University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham
Prebieha nábor
Vek 18 až 99 · Všetky pohlavia · Aktualizované 31. 10. 2025 · NCT03643861SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
Prebieha náborObservačná štúdia
Všetky vekové kategórie · Všetky pohlavia · Aktualizované 28. 10. 2025 · NCT03452774Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.